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Pharmacological Chaperone Therapy for Gaucher Disease – A Patent Review 
 
Abstract 
Introduction. Mutations in the gene encoding for acid -glucosidase (-
glucocerebrosidase, GlcCerase) are in the origin of Gaucher disease (GD), the 
lysosomal storage disorder with the highest prevalence. Such mutations in GlcCerase 
give rise to significant protein misfolding effects during translation in the endoplasmic 
reticulum and reduction in enzyme trafficking to the lysosome, which result in 
progressive accumulation of glucosylceramide (GlcCer). The main treatment for 
Gaucher disease is enzyme replacement therapy (ERT), in which defective GlcCerase is 
supplemented by active enzyme. The iminosugar glycosidase inhibitor N-(n-butyl)-1-
deoxynojirimycin (NB-DNJ; miglustat, ZavescaTM) is used in a second treatment 
modality known as substrate reduction therapy (SRT). At the beginning of the 21st 
century a third therapeutic paradigm that advocates the use of active site-directed 
competitive inhibitors of the enzyme to restore its activity in the lysosome, namely 
pharmacological chaperone therapy (PCT), was launched. This counterintuitive strategy 
relies in the capability of such inhibitors to promote the correct folding and stabilize 
mutant forms of lysosomal enzymes, such as GlcCerase, as they pass through the 
secretory pathway.  
Areas covered. This review summarizes the different approaches to implement the 
concept of pharmacological chaperone therapy for Gaucher disease by discussing the 
relevant research, patents and patent applications filed in the last decade. 
Expert opinion. Ten years after PCT was first suggested, the time has come to dissect 
whether the expectations were well founded or not on the basis of the transfer of the 
concept to the clinics. While the significance of PCT remains a matter of debate, the 
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great interest gathered in relatively few years reflects its broad potential scope, well 
beyond GD. In fact, the resolute involvement of the pharmaceutical industry cannot be 
explained on the basis of the limited economical revenue associated to GD therapies but 
on a long-term view that focuses on the potential of the PCT concept in many other 
protein-folding diseases. The fact that PCs can be designed to cross the blood-brain 
barrier makes them candidates for the treatment of neuronopathic forms of GD that are 
not responsive to ERT. Combined therapies offer even broader possibilities that deserve 
to be fully explored. 
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storage disorders; Nojirimycin; Pharmacological chaperone therapy 
 
3 
 
1. Introduction 
The lysosomes are cellular organelles specialized in the enzymatic digestion and 
recycling of exogenous and endogenous cellular debris. Lysosomal catabolic pathways 
normally involve the regulated action of a series of enzymes; inappropriate performance 
of any of the multiple hydrolytic enzymes involved in these cascades may lead to 
abnormal storage of undegraded substrates. Excessive accumulation of some of these 
substances is at the origin of a variety of cellular dysfunctions that can potentially lead 
to a range of pathologies commonly known as lysosomal storage disorders (LSDs) [1-4]. 
LSDs are a clinically heterogeneous group of genetically inherited (most of them in an 
autosomal recessive pattern) disorders often (but not solely) caused by the deficiency in 
the activity of a particular lysosomal enzyme. 
There are over 60 different LSDs characterized by the lack of sufficient enzymatic 
activity to prevent the accumulation of specific substrates. Each unique disorder is 
caused by deficiency or dysfunction of a different enzyme [1]. The most prevalent 
group is associated to the abnormal storage of glycosphingolipids, a complex family of 
structural components of mammalian cell membranes that are involved in fundamental 
processes such as cell adhesion and signal transduction modulation [5]. LSDs are 
classified according to the accumulated metabolite and named after the physicians that 
firstly reported their clinical manifestations (Table 1). Each individual LSD is rare, 
though altogether their estimated incidence is one in 5000 to 10000 live births in 
Western countries, which is only slightly less common that cystic fibrosis (CF), one of 
the most frequently occurring genetic diseases. However, the extremely diverse 
phenotypic and pathophysiologic profiles, from virtually asymptomatic to serious 
neurological affections, have consistently hampered diagnosis and investigation for 
decades. In fact though most of LSDs were identified in the 19th century, lysosomal 
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involvement was not established until the 1960’s [6], just few years after lysosome 
organelles were discovered [7]. Among the different therapeutic approaches under 
investigation, parenteral infusion of exogenous enzymes to process accumulated 
substrate (enzyme replacement therapy, ERT) has been shown so far the most effective 
[8]. Although ERT has proven beneficial for the most prevalent LSDs, including the 
most prevalent types of Gaucher (-glucocerebrosidase deficiency) or Fabry (-
galactosidase A deficiency) diseases, many other LSD patients still remain untreated. A 
second treatment modality known as substrate reduction therapy (SRT) consists in the 
administration of an inhibitor of the biosynthesis of glucosylceramide through 
inactivation of a ceramide glucosyltransferase, glucosylceramide synthase, thereby 
limiting accumulation of GlcCer [9]. In the last decade, a new therapeutic approach 
focused on recovering the activity of the endogenous dysfunctional enzymes, namely 
the pharmacological chaperone therapy (PCT; the term chemical chaperone therapy is 
indistinctly used in the literature), has emerged as a promising alternative [10]. This 
review will dissect the contribution of PCT to the advance in enzymopathy treatment of 
Gaucher disease, the LSD with the highest prevalence and often considered as a model 
for other LSDs, emphasizing on those that were translated into protected applications 
and technologies. 
 
2. Protein folding in lysosomal storage disorders 
The origin of protein dysfunction causing LSDs is diverse; however, abnormal protein 
folding during biosynthesis in the endoplasmic reticulum (ER) is often observed. As in 
many other diseases caused by protein misfolding, such as cystic fibrosis or 1-
antitrypsin deficiency, certain inherited genetic deficiencies are translated into aberrant 
peptide sequences with reduced folding capabilities [11]. Lysosomal enzymes are 
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normally synthesized via the rough endoplasmic reticulum in each cell. They are then 
trafficked to the Golgi for maturation and finally targeted to the lysosome (Figure 1, 
Pathway A). Trafficking between the ER and the Golgi apparatus is however interrupted 
when, as a consequence of certain gene mutations, the expressed proteins do not fold 
properly. Since ensuring accuracy in cellular functions critically depends on correct 
protein folding, cells have evolved their own protein quality control systems, namely 
the ER-associated protein degradation (ERAD) pathway, that efficiently clear off 
proteins that do not fold correctly or within the expected time frame in the ER (Figure 1, 
Pathway B). Ironically, in spite of their conformational deficiencies, in many of the 
misfolded lysosomal enzymes the catalytic site is preserved and would still be active 
enough in the lysosome to prevent abnormal substrate accumulation but, as a 
consequence of the severity of the protein quality control system, they would never 
have the opportunity to exert its function. 
A variety of characterized gene mutations, ranging from single base substitutions to 
whole gene deletions, are known to lead to deficient enzyme or enzyme activity 
associated to LSDs [12-16]. The severity of disease manifestation is somewhat linked to 
the residual activity of the mutant enzyme. In the most dramatic cases patients, infants, 
are often developmentally or mentally retarded and rarely survive the first year of life. 
In other cases, symptoms only appear during adulthood due to progression of substrate 
accumulation (Table 1). The therapeutic goal of the various approaches to treat 
lysosomal enzymopathies is to restore the balance between the influx and degradation of 
the accumulated substrates (Figure 2).  
 
3. The Gaucher disease 
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Gaucher disease (GD), named after the French physician Phillipe Gaucher who 
described the symptoms in 1882 [17], is a lysosomal storage disorder associated to the 
dysfunction of -glucocerebrosidase (acid -glucosidase, GlcCerase; EC no.3.2.1.45) 
that results in the accumulation of glucosylceramide (GlcCer) [18]. Accumulation 
usually takes place preferentially in macrophages but also in organs such as the liver, 
spleen, kidney, lung and even the brain and bone marrow. GD, caused by a recessive 
mutation in a gene located on chromosome 1, is the most prevalent LSD and affects 
overall to one in each 20000 live births on the basis of epidemiologic studies performed 
in the developed countries (Table 1) [19].  Nevertheless, in certain populations the 
frequency is much higher: among the Ashkenazi Jews, one in 450 to 800 live births 
(depending on the data source) is affected by GD. Little data are available from the 
situation in under-developed countries, but growing consciousness of GD frequency in 
developing regions such as Asia and South America clearly points to a pan-ethnic 
incidence. 
As a consequence of the variety of organs affected by glucosylceramide accumulation, 
disease manifestation may differ between different patients. Visceral (e. g. 
splenomegalia and hepatomegalia), blood (e. g. anemia and thrombocytopenia), bone, or 
neurological affections are the most common symptoms; however the precise 
mechanisms by which glucosylceramide storage originate them is still unclear. A broad 
series of other less typical presentations have also been reported [20]. While 
visceromegalia is generalized in all cases, the incidence of the other phenotypes is, to 
some extent, related to the variant of the disease (Table 2).  
There are three clinical GD disease variants, depending on the severity of the 
neurological involvement. Type 1 GD, also known as the non-neuronophatic or adult 
variant (Mendelian Inheritance in Man number MIM#230800), is the most common and, 
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as a consequence, the best characterized of all LSDs. However, symptomatology, 
severity and progression are heterogeneous in type 1 GD patients. In fact disease 
manifestation varies from childhood to adultness, indistinctly. Type  2  (MIM#230900) 
and type 3 (MIM#231000) variants involve neuronopathic affections. In type 2 GD 
there is a rapid progression of the disease that severely affects the central nervous 
system (CNS) in newborns and very rarely patients survive the second year of life. In 
type 3 GD progression is slower and disease shows up from childhood or adolescence 
(Table 2).  
Diagnosis of Gaucher disease has usually been performed by measuring -
glucocerebrosidase activity in cultured cells (e. g. peripheral blood leucocytes or skin 
fibroblasts) [21], but DNA-profiling techniques are taking over. DNA testing has 
improved diagnostic accuracy not only for patients but also for carrier individuals and, 
in addition, may facilitate building up intimate genotype/phenotype correlations [22-24]. 
Over 300 mutations have been so far characterized [25], though two of them 
(c.1226A>G leading to N370S and c.1448T>C leading to L444P) were found in more 
than 60% of the cases (Table 3). According to calculations based on the X-ray structure 
of the native enzyme, most of the mutations would induce only minor conformational 
and activity drops [26]. Despite this knowledge, the ability to make prognostic 
predictions from genotypic data is rather limited. The N370S allele is by far the most 
common mutation, affecting to ca. 1% of US population (6% of Askenazy Jews) [27]. 
In Western countries, an association can be drawn between the presence of the N370S 
allele in combination with other mutation and type 1 GD. Conversely, the L444P allele 
is most frequently associated to the neuronopathic variants.  
In spite of the limited knowledge of certain key molecular aspects, due to the 
heterogeneity of manifestations in a relatively small clinical population, Gaucher 
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disease is considered a suitable model for other less common but equally devastating 
LSDs. In fact it has been tacitly accepted that therapeutic innovations towards the 
different variants of GD, apart from the obvious benefit for GD patients, may anticipate 
a brighter future for those affected by other LSDs. 
As above outlined, the obvious therapeutic goal towards GD is to achieve equilibrium 
between the biosynthetic and degradation pathways within the cell in order to maintain 
homeostasis. Therefore, the enzymes responsible for the biosynthesis and degradation 
of glucosylceramide (glucosylceramide synthase and -glucocerebrosidase, 
respectively) have emerged as the most important therapeutic targets in GD [28]. 
Different strategies to inhibit the former or activate, rescue or supplant the latter have 
been investigated in the last decades [3]. 
 
4. Therapeutic milestones and pitfalls in Gaucher disease 
As a consequence of the relatively small number of individuals affected by and their 
heterogeneity, Gaucher disease has certainly never been attractive for the 
pharmaceutical industry, which is also true for other LSDs. Initial therapeutic 
approaches were restricted to symptom management, including pain relief, blood 
transfusions, orthopedic surgery, and organ removal. For ages, the sole pipeline to 
feedback alternative therapeutic development resulted from the knowledge in lysosomal 
functioning gained from academic research. Within orphan drug legal frame, however, 
the 80’s have witnessed the transference of this knowledge into therapeutically useful 
LSD treatments. This fact, together with the rising market associated to LSD 
management (estimated in US$ 2.8 billions), has woken the interest of pharmaceutical 
companies. The therapeutic approaches developed over the years are chronologically 
collected in Figure 3. 
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The first successful treatment for GD, enzyme replacement therapy (ERT), was 
introduced in the clinics at the beginning of the 90’s. The therapy consists on the 
infusion of an exogenous recombinant enzyme to take over the mission that the 
endogenous mutant one is unable to perform (Figure 4C) [3,8]. Many of the visceral and 
skeletal manifestations of GD vanish upon regular treatment with a recombinant -
glucocerebrosidase. The fact that patients may recover their quality of life within 2-3 
years has given ERT a privileged therapeutic status. Genzyme has remained as the sole 
supplier for this type of therapeutics for GD ever since (imiglucerase or Cerezyme®) 
but very recently a new enzyme preparation (Velaglucerase , VPRI®, Shire Human 
Genetic Ther, USA) has been approved by FDA [29], and a second one (Taliglucerase , 
Uplyso®, Protalix BioTherapeutics, Israel) is expected to get approval shortly [30]. 
Furthermore, ERT in Gaucher disease has been considered a paradigm that inspired 
similarly successful approaches. Several promising candidates towards other LSDs are 
presently either approved by FDA (e. g. Fabrazyme™ from Genzyme, in Fabry disease) 
or in advanced clinical trials [1,31,32]. 
Unfortunately, the scarce permeability of the blood-brain barrier to macromolecules 
limits ERT efficiency to non-neurologically affected GD individuals (type I). Type  2  
and type 3 GD patients cannot benefit from this therapy. In addition, the cost of a single 
treatment (100-200 k$ per patient per year) that would require lifelong commitment 
makes judicious use of the therapy mandatory. 
A conceptually complementary approach to ERT is the reduction in the influx of the 
accumulated substrate. Provided a residual -glucocerebrosidase activity is remaining 
(which is the case in most GD patients), inhibition of the substrate producing enzyme 
may facilitate clearance (Figure 4D) [9,33]. The concept of substrate reduction therapy 
(SRT) was first demonstrated in GD by Shukla and coworkers by using a small 
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molecule inhibitor of glucosylceramide synthase [34]. The use of small molecule 
inhibitors (e. g. iminosugars) for the treatment of GD instead of recombinant enzymes 
was very sound in order to develop more “drugable” candidates with better BBB 
permeability [35,36]. Unfortunately, SRT has not succeeded so far in bringing up 
suitable candidates for treatment of neuronophatic variants [37] and still the benefits of 
the treatment in type 1 GD do only recommend this therapy in patients naïve to ERT 
[38]. The most representative of this type of compounds, N-butyl deoxynojirimycin 
(NB-DNJ, Miglustat™, Actelion Pharma, Switzerland) was approved by the FDA and 
EMEA in 2003 for use in adults with type 1 GD who have medical contraindications to 
enzyme replacement therapy. Similar drug-based therapies are also being investigated in 
advanced clinical trials for Fabry, Tay-Sachs, Sandhoff, Niemann-Pick diseases or GM1 
gangliosidosis [39]. 
So far, ERT and SRT are approved medical treatments for GD that have significantly 
contributed to improve the life quality of type 1 patients. However, they still are 
inefficient to target the central nervous system (CNS). Managing neurological affections 
represents nowadays the major challenge. Gene therapy (GT) [40,41] and stem cell 
therapy (SCT) [42,43] or bone marrow transplantation (BMT) [12,44], long-term 
promises towards this end, have slowed down their progress due to the problems 
associated to mutagenesis and malignant-cell transformation [45-47] or donor 
limitations and procedure-associated risks. 
 
5. Pharmacological chaperone therapy. 
As already discussed, most LSDs stem from the insufficient enzymatic activity in the 
lysosome as a consequence of the poor trafficking of a misfolded enzyme. A decade ago 
a pioneering report by Fan and co-workers demonstrated that in certain cases small 
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molecule ligands of a mutant glycosidase enzyme (e. g. substrate-like competitive 
inhibitors) might promote those conformational changes that are required for efficient 
folding [48]. Though subtle, this chaperoning activity seems to be instrumental in order 
to rescue the enzyme from ERAD and deliver it through the appropriate pathways to its 
final destination in the lysosome [1,49]. It is assumed that at the massive lysosomal 
substrate concentration, the inhibitor would be replaced from the active site of the 
enzyme and the metabolic activity recovered (Figure 4E). This counterintuitive concept 
(namely, using inhibitors to elicit enzyme activity) set the basis for a brand new 
therapeutic approach to LSDs: the pharmaceutical chaperone therapy (PCT). Proof of 
principle of the feasibility of this therapeutic approach has been given for some of the 
most relevant LSDs, including GM1gangliosidosis [50], Fabry disease (FD) [51], Pompe 
disease (PD) [52] and, of course, GD [53]. 
Conceptually, rescuing mutated proteins using sub-inhibitory concentrations of 
pharmacological chaperones (PCs) is advantageous as compared to the established 
therapies (ERT and SRT). PCT aims to achieve a therapeutic effect without the 
administration of potentially immunogenic exogenous proteins (ERT) or disregulating 
the glycosphingolipid metabolic pathways (SRT). Rather than focusing in reducing the 
influx of substrate (SRT), PCT tackles the cause of the accumulation by mending the 
functionality of the endogenous enzyme. In addition, the use of PCs has the potential to 
overcome the limitations of ERT concerning biodistribution (in particular concerning 
BBB permeability), administration (requiring lifelong regular infusions) and eventually 
costs. It has been demonstrated that some pharmacological chaperone candidates cross 
over the BBB, therefore being potentially useful for the treatment of patients with 
neuronophatic affections. For instance, NB-DNJ, used in SRT modality for GD and a 
potential chaperone for the acid -glucosidase involved in Pompe disease, evenly 
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distribute in a variety of tissues in model animals [54] and NOEV (N-octyl-4-epi--
valienamine), a chaperone for the-galactosidase involved in GM1 glangliosidosis, is 
rapidly localized in most areas of the brain [50] (Table 4).  
There are also some inherent limitations for PCT. The mutant enzyme should be (at 
least residually) active in the lysosome since the chaperoning activity in the ER would 
only improve protein folding, ERAD evasion and trafficking to the lysosome. If 
mutations affect the catalytic pocket, PCT is very likely to fail [55]. In addition, this 
chaperoning activity at the ER should be achieved at sub-inhibitory concentrations 
under lysosomal conditions and, therefore, a balance between folding enhancement and 
enzyme inhibition should be reached for each particular case. 
In spite of these drawbacks, PCT has attracted a great interest in a relatively short 
timeframe stimulating a particularly fruitful synergy between academia and industry 
that has spread among several LSDs as well as other genetic protein folding disorders 
such as cystic fibrosis [56]. For instance, Miglustat™, already approved by FDA for the 
SRT modality of type 1 GD, is currently in phase II clinical trials for the treatment of 
cystic fibrosis [57]. At glance, the field is maturing fast in particular for the case of GD 
[53]. Many of the mutations associated to GD are located in the catalytic domain (e. g. 
N370S), however they rarely affect the catalytic pocket and, therefore, the metabolic 
activity is preserved to certain extent [58]. In such scenario, where the folding hurdle is 
associated to the enzyme active site, the investigation of substrate-like competitive 
enzyme inhibitors as pharmacological chaperones is particularly sound. This effort is 
translated into a growing arsenal of newly designed pharmacophores and applications. 
The substantial patenting activity in the field reflects the high expectations created 
around PCT. The most promising patent contributions concerning pharmacological 
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chaperon therapy in Gaucher disease are collected in Table 5 and summarized in the 
following sections. 
 
6. Design of new pharmacological chaperones towards Gaucher disease 
Even though inducing the appropriate folding in a mutant protein can be achieved with 
chaperones that interact with any region on the protein, the search for molecular 
structures that could function as pharmacological chaperones has been largely 
dominated by the use of active-site specific ligands. The fact that such type of ligands (e. 
g. competitive enzyme inhibitors) can be rationally designed on the basis of enzyme 
structure knowledge is a main reason for this channel. Another one is the fact that many 
of the mutations associated to GD are actually located in the catalytic domain. 
Consequently, a significant amount of effort has been directed to bring up new 
pharmacophores that can fit in the GlcCerase active site and clamp the correct folding. 
Three basic premises are considered necessary to successfully achieve this task, namely 
high enzyme affinity and selectivity at the ER in order to induce the proper folding, 
suitable permeability and biodistribution and smooth dissociation from the enzyme at 
the lysosome. Most of the protocols seeking for potential pharmacological chaperones 
towards LSDs in general and GD in particular are based on the sequential consisting on 
(i) the identification of compounds that selectively inhibit the target enzyme from more 
or less diverse chemical libraries (in vitro), (ii) investigation of the mutant enzyme 
activity enhancement capability of the most interesting candidates in cell-based assays 
(ex vivo), and (iii) pathophysiologic evaluation in animal models (in vivo) [59]. 
 
7. Glucocerebrosidase substrate-like pharmacological chaperones towards 
Gaucher disease 
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Iminosugars, the most prominent family of naturally occurring glycosidase inhibitors, 
hold a privileged status in the search for efficient chaperone candidates for PCT. 
Iminosugars resemble the structure of natural glycosides, except for the presence of a 
nitrogen atom in place of the endocyclic oxygen of the substrate [60,61]. They generally 
feature high affinity for the active site of glycosidases according to their hydroxylation 
pattern, eventually higher than the natural substrates, therefore acting as glycosidase 
inhibitors. In most cases, the therapeutic potential of the glycosidase inhibition 
capability of naturally occurring iminosugars is limited due to their rather poor 
selectivity within enzymes acting on anomeric glycosides (e.g., simultaneous inihibition 
of - and -glucosidases) as well as within isoenzyme series (e.g., simultaneous 
inhibition of neutral and acid -glucosidases). Nevertheless, in certain cases a useful 
chaperoning activity has been encountered in addition to their glycosidase inhibition 
capability. As a matter of fact, iminosugars were the first type of compounds 
systematically investigated as pharmacological chaperones and still are the main source 
of investigational drugs for GD and many other LSDs [62]. 
In one of the first examples of the above working procedure, Kelly and coworkers 
investigated the chaperoning abilities of a structurally diverse collection of compounds 
towards human GlcCerase, including natural and alkylated iminosugars [63]. This study 
lead to the discovery that sub-inhibitory amounts of N-nonyldeoxynojirimycin (NN-
DNJ, Chart 1) could be used to restore the -glucocerebrosidase deficiency in cultured 
fibroblasts expressing the type 1 GD mutation N370S [64, 201]. The structural 
resemblance of this newly identified -glucoserebrosidase chaperone with NB-DNJ 
(approved for SRT in type 1 GD in 2003) has called the attention on the reinvestigation 
of the precise role of the latter in glucosylceramide management. Thus, Pocovi and 
coworkers have demonstrated that, in addition to the well documented substrate-
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deprivation effect, NB-DNJ leads to significant activity increases for several mutant -
glucoserebrosidases (e. g. 2-fold increase in the N370S mutant) expressed in COS-7 
(immortalized African green monkey kidney fibroblast) cells [65]. 
Besides NN-DNJ, other alkylated iminosugars were identified from this library as 
potential pharmacological chaperones for mutant -glucocerebrosidases associated to 
GD. For instance, N-octyl-2,5-anhydro-2,5-imino-D-glucitol has been shown to 
preferentially enhance the activity of the G202R mutant [64]. Up to 7-fold increases in 
enzyme activity were observed with isofagomine derivatives alkylated with sterically 
bulky adamantane substituents (Chart 1), though the chaperone concentration required 
to achieve this activity enhancement (>100 M) is probably unpractical from the 
therapeutic point of view [66]. However, none of these chaperones were effective for 
the L444P mutant enzyme, associated to neuronopathic GD variants. 
In a different invention, Fan and coworkers reported that minute amounts of N-dodecyl 
DNJ could elicit -glucocerebrosidase activity (95% activity increase at 0.5 M) in 
cultured N370S fibroblasts. Naturally occurring calystegine B2 (Chart 1) and other 
memers of the calystegine iminosugar family were claimed to exhibit a very significant 
chaperone activity in fibroblasts from a Gaucher patient with the L444P/L444P 
genotype (230% activity increase at 10 M for calystegine B2) [202-204]. This is 
remarkable considering that the L444P mutation is not located at the catalytic domain of 
GlcCerase and has been shown to be generally refractive to active-site directed chemical 
chaperones. Unfortunately, these results have not been the object of further publication 
and remain to be confirmed. Additionally, these inventions showed the first evidences 
of the chaperoning properties of isofagomine [67] and isofagomine derivatives towards 
-glucocerebrosidase. 
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Isofagomine (IFG, Chart 1) is probably so far the most representative investigational 
pharmacological chaperone for GD. IFG strongly binds to wild-type and mutant -
glucocerebrosidases (IC50 60 nM), helping misfolded mutants to fold correctly. In vitro 
studies have shown that IFG enhances 2-to-3 fold the activity of N370S mutant -
glucocerebrosidase. IFG enhances mutant enzyme activity by assisting folding in ER 
and lowering the optimal enzyme working pH (from 6.4 to 5.2, closer to that found in 
the lysosome) [68]. Additionally, it has been shown that IFG plays a role in the enzyme 
trafficking enhancement [67]. Interestingly, these effects are achieved at relatively low 
concentrations, therefore limiting the adverse effects associated to the non-specific 
inhibition of other lysosomal or intestinal glycosidases [69].  
Under the enthusiastic sponsorship of Amicus Therapeutics, synthetic approaches 
towards IFG (AT-2101, Plicera®) [205,206] and formulations [207,208] have arisen. 
Recent results have shown that IFG can reduce glucosylceramide levels even in L444P 
Gaucher fibroblasts. Importantly, this reduction was seen only following three-day 
incubation in IFG-free media, underscoring the importance of IFG removal to restore 
lysosomal GCase activity. Investigations in knock-in mouse models expressing L444P 
mutated -glucocerebrosidase have evidenced dose-dependent enzyme activity increase 
(2 to 5 fold) in the brain [70,209]. Preliminary reports indicated that these effects were 
achieved within few weeks and are persistent after treatment withdrawn. In addition, a 
recently reported procedure for the monitoring of typical GD surrogate markers [210] 
indicated the progressive healthy cell functioning recovery upon IFG treatment. Using 
this GD surrogate markers monitorization procedure, formulations and tolerable dose 
regimes have been implemented for humans [211]. 
IFG has completed a phase II study [71] in patients receiving ERT and several others 
are in course to assess ex vivo response to the drug [72], its long term effects [73] and 
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its safety, tolerability and efficacy in treatment-naive adult type 1 GD patients [74]. 
Unfortunately, the preliminary results of the latter study revealed scarce improvement in 
key GD markers and manufacturers do not expect IFG to enter Phase III development 
[75]. The high hydrophilicity of IFG is probably in part responsible for its poor 
performance in humans. 
In order to avoid this drawback, less hydrophilic IFG derivatives are being alternatively 
investigated. C-Alkylated derivatives such as 6-nonyl IFG [212,213] (Chart 2) has been 
shown to increase -glucocerebrosidase activity. While enzyme activation is not 
significantly higher than that reported with IFG, the concentration required to achieve it 
is several orders of magnitude smaller: whereas IFG achieves optimal enzyme activity 
at 30 M, 6-nonyl IFG did at 3 nM in cultured N370S human fibroblasts.  
The presence of aliphatic chains in iminosugars may results in loose of selectivity as 
compared to the parent structures, due to non- specific interactions with hydrophobic 
pockets in the surroundings of the glycosidase binding site. As an alternative mode to 
reduce the hydrophilicity of IFG without affecting enzyme selectivity, Boyd and Lee 
disclosed halogenated IFG derivatives (F-IFG and Cl-IFG, Chart 2) [214,215]. Similarly 
to IFG, F-IFG and Cl-IFG are strong competitive glucocerebrosidase inhibitors in vitro 
(inhibition constant, Ki, in the low nM range). However, in contrast with the former, the 
efficiency does not significantly decrease in cell-based assays, pointing to more 
favorable membrane-crossing capabilities for halo-IFGs. In vivo assays in mice further 
indicated interesting blood-brain barrier permeability. Halo-IFG extensively localized in 
the brain and induce a 2-to-3 fold increase in glucocerebrosidase activity at 10 mg·Kg-1 
(less than 10% of IFG dose required to elicit the same response). 
Besides the thorough research around IFG and IFG derivatives sponsored by Amicus 
Therapeutics, many other iminosugar-based designs are under investigation. Most of 
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them aim at improving the selectivity towards the target enzyme, a typical problem 
when using classical iminosugars. For instance, in addition to the chaperoning effect on 
the N370S mutant -glucocerebrosidase, NN-DNJ also produces a potentially 
dangerous inhibition of the lysosomal -glucosidase. In other to prevent this drawback, 
Asano and coworkers investigated alternative alkylation patterns that led to the 
identification of -1-C-octyl-DNJ (CO-DNJ, Chart 3) [76]. Later they found that -1-
C-nonyl-iminoxylitol (CN-DIX, Chart 3) was a much more selective inhibitor of 
GlcCerase [77,216]. Although the chaperoning capability of these iminosugar pseudo 
C-glycosides is smaller than that reported for NN-DNJ (1.7 to 2.0 fold and 1.2 fold 
activity enhancement in N370S and L444P Gaucher fibroblasts, respectively), they are 
remarkably selective and therefore do not interfere with the activity of other lysosomal 
or intestinal glycosidases.  
In a different invention, Fan and coworkers reported a series of alkylated 
glucoimidazoles (alkyl-GIZ, Chart 3) as new potential -glucocerebrosidase 
chaperones . The -glucocerebrosidase inhibiting potency of these derivatives is 
remarkably high (IC50 in the pM range in certain cases), however the selectivity issue 
was not addressed and the enzyme activity in cultured N370S patient cells only 
increased 2-fold upon incubation with GIZ (300 M) [217,218].  
Glycosidase selectivity and membrane permeability are critical parameters that must be 
taken into consideration in the design of new pharmacological chaperones. Committed 
with these principles, a recently reported invention exploits the concept of “sp2-
iminosugars” [78] for this purpose. It has been demonstrated that bicyclic iminosugars 
that incorporate a bridgehead nitrogen atom with substantial sp2 character (instead of the 
sp3 hybridization typical of classical iminosugars) behave as competitive inhibitors of 
glycosidases with tunable selectivity [79-84]. Bicyclic sp2-iminosugar analogues of the 
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natural reducing alkaloid nojirimycin (NJ; note that these compounds can be formally 
considered as reducing indolizidine-type glycomimetics) bearing lipophilic substituents, 
such as 5-N,6-O-(N’-octyliminomethylidene)nojirimycin (NOI-NJ) or its 6-thio 
derivative (6S-NOI-NJ) (Chart 3), are anomeric-specific inhibitors of -glucosidases, 
including the lysosomal acid -glucosidase associated with Gaucher disease [219]. The 
inhibitory activity was preserved for a range of glucocerebrosidase mutants including 
F213I, N370S and L444P. Furthermore, the inhibition potency was systematically 
stronger at neutral (7.0, ER) than at acidic (5.2, lysosomal) pH, which is expected to be 
favorable in order to promote chaperoning at the ER and further enzyme trafficking 
without compromising hydrolytic activity once at the lysosome. Mutation profiling of 
the chaperone effect of sp2 iminosugars evidenced relatively modest activity 
enhancements for the N370S mutation as compared with NN-DNJ. However in situ 
cell-based assays using patient fibroblasts revealed much higher activity increases (ca. 
2.5 fold) for mutant enzymes associated to neuronopathic GD affections (F213I or 
G202R) [85]. An additional advantage of sp2 iminosugars in comparison with other 
pharmacological chaperone cores is that the synthetic scheme is very well-suited for 
molecular diversity-oriented strategies and therefore it might be possible to discover 
new candidates with improved chaperoning capabilities and high selectivity by finely 
tuning the molecular structure. 
In addition to iminosugar-based scaffolds, other glycomimetic structures, e.g. 
aminocyclitols, have shown interesting chaperoning capabilities. In a pioneering report, 
Ohno and Suzuki demonstrated that N-octyl--valienamine (NOV, Chart 4), a -
selective glucosidase inhibitor [86], up-regulates certain mutant -glucocerebrosidases 
in cultured fibroblasts [87,88]. The best results (6-fold activity enhancement) were 
obtained for the F213I mutation. Interestingly, the epimeric analog resembling the 
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galactose configuration (N-octyl--3-epi-valienamine NOEV) has also been shown to 
chaperone mutant acid -galactosidases involved in GM1 gangliosidosis [89]. 
More recently, Delgado and coworkers have identified a series of selective -
glucosidase inhibitors from a library of N-alkyl aminoinositols. Although their 
chaperoning activity is relatively modest [58], some of these compounds are able to 
stabilize imiglucerase, the recombinant enzyme used for ERT, when subjected to 
thermal denaturation conditions [220]. Imiglucerase stabilization is somehow dependent 
on the length of the alkyl chain, the best results being obtained with the longest 
(hexadecyl) aliphatic chain [90] (Chart 4). 
 
8. High-throughput library screening towards pharmacological chaperones for 
Gaucher disease 
The cumulative data commented in the previous sections stress the necessity of a 
thorough mutation-based profiling of chemical chaperones to evaluate their therapeutic 
potential. Ideally, the information collected from screening should allow designing 
tailor-made chaperones for different mutant enzymes. Rational design of 
pharmacological chaperones still faces some important limitations, however, including 
the rather scarce number of molecular scaffolds at hand and the limited knowledge of 
the 3D structure of the target mutant enzymes. Most of the newly developed candidates 
are compounds with a glycomimetic topology stemming from enzyme inhibition studies 
that never have been tested in humans before and, therefore, they have first to be 
approved by the legal authorities. 
In a desperate attempt to take a shortcut in the way to identify new potential 
pharmacological chaperones, several generic libraries have been assayed for thermal 
enzyme denaturation inhibition capability using high-throughput screening (HTS) 
21 
 
techniques. The potential of this approach to lead to positive heats as potential chemical 
chaperones is paradigmatically illustrated with the case of Ambroxol (ABX, Chart 5). 
ABX is a mucolytic drug approved for its use in newborns that was identified among 
other 1039 FDA-approved small molecules as a very efficient stabilizer of the 
recombinant enzyme imiglucerase in thermal denaturation conditions [221]. ABX-
mediated thermal stabilization has been demonstrated for wild-type and mutant -
glucocerebrosidases. The interaction between ABX and -glucocerebrosidase results in 
a very interesting inhibition pattern: it switches from highly efficient at neutral (ER) pH 
to virtually undetectable in acidic (lysosome) conditions. These features are probably 
responsible for observed enhancement in mutant (N370S and F213I) glucocerebrosidase 
activity, up to 6-fold as determined in human fibroblasts [91,221]. 
The discovery of ABX represents a milestone in the search for therapeutic treatments 
for GD that will surely influence further research on other LSDs. So far, most of the 
strategies were focused on screening candidates selected on the basis of their 
glycosidase inhibition capabilities, assuming that active-site specific ligands are the best 
potential candidates to help enzyme trafficking and restore enzyme activity. However, 
HTS has opened the door to evaluate a much wider diversity of structures not 
exclusively targeted to the enzyme active site. Ironically, while in principle ABX could 
potentially interact with the -glucocerebrosidase at any position, hydrogen/deuterium 
exchange mass-spectrometry and molecular modeling experiments indicate that binding 
takes place at the catalytic domain [91]. On the other hand, the initial screening 
principle, focused on glycosidase stabilization rather than on inhibition, may also be 
considered better suited for the final therapeutic goal. 
The case of ABX is not anecdotic. Screening of the same library versus the -
hexosaminidase involved in GM2 glangliosidosis let the same authors to identify 
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pyrimethamine as a potential chemical chaperone for this enzyme [92,222]. Regrettably, 
phase I clinical trials [93] were recently suspended due to insufficient funding.  
From a thorough preliminary screening of the Maybridge library (ca. 50000 compounds, 
see www.maybridge.com) a number of non-carbohydrate small molecules were 
identified as selective -glucocerebrosidase inhibitors. A focused screening of the most 
active compounds showed that certain structures featured chaperoning activity towards 
N370S mutant -glucocerebrosidase, though not necessarily correlated to their 
inhibitory potency. The most interesting structures, 5-(3,5-dichlorophenoxy)-N-(4-
pyridinyl)-2-furamide (HTS02324) and 5-(4-tolylthio)quinazoline-2,4-diamine 
(MWP01127) (Chart 5), are mixed-type glucocerebrosidase inhibitors with optimal 
performance at neutral pH and poor binding at acidic pH. This feature, together with 
their membrane permeability, is probably the reason for their efficient performance: 1.5-
2.5-fold enzyme activity enhancements were measured in GD fibroblasts (homozygote 
N370S and F213I mutations) using as little as 10 M of HTS02324 and MWP01127. 
This performance is not far from that obtained with IFG, a much stronger 
glucocerebrosidase inhibitor (IC50 values 0.06, 5 and 8 M for IFG, HTS02324 and 
MWP01127, respectively) [223,224]. 
 
9. Computational discovery of pharmacological chaperones for Gaucher disease 
In addition to the above commented methods for identifying new pharmacological 
chaperones to promote the appropriate folding of mutant -glucocerebrosidases,  
Futerman and co-workers disclosed a computational platform to design optimal GD-
targeted drugs [225]. Their invention consists on a method to generate sets of 3D-
coordinates of mutant -glucocerebrosidases on the basis of the available 
crystallographic data, from which the structure of compounds capable of correcting the 
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impaired enzyme activity could be computationally optimized. While the proof of 
concept was not completed in the invention report, the potential of computationally 
assisted pharmacological chaperone design is expected to improve as more structural 
data on GlcCerase:chaperone complexes become available. 
 
10. Expert Opinion 
The body of results commented and the relatively short time span in which they were 
generated stresses the prospects of PCT towards GD. The enthusiastic support of the 
pharmaceutical industry (it is important to highlight that the knowledge developed in 
the field does not arises exclusively from the academic field) cannot be understood as a 
mere commercial interest on GD treatment because the potential market, though eager 
for receiving improved treatments, is very limited. This attitude may reflect the potential 
of PCT as a general approach to the growing diversity of diseases associated to 
inappropriate protein folding, which is not limited to LSDs but includes also several 
pathologies that represent major health problems in developed countries. Thus, some 
recent results have established a link between GD and Parkinson disease [94-96].  
It is worth mentioning that the first proof-of-concept of PCT did not concern a LSD-
associated enzyme, but mutant forms of theV2 vasopressin receptor (V2R), which by 
failing to traffic to the cell membrane causes nephrogenic diabetes insipidus [97]. Any 
molecule capable of promoting structural adaptation is a potential pharmacological 
chaperone, including inhibitors (if reversibly bound), as shown for various V2R mutants 
in this pioneer study and further on in several LSDs. The key aspect is specificity: 
pharmacological chaperones exert a specific action on a given target molecule [10]. It 
should be emphasized that repair by pharmacological chaperones implies an almost 
“mutation-specific” mode of action, inasmuch as their binding is determined by a 
24 
 
particular conformation possibly not common to all mutant forms of a given receptor. 
Investigations on the use of pharmacological chaperones to correct protein 
conformational defects associated with a variety of human diseases, including prion 
disease, Alzheimer disease, retinitis pigmentosa, cancer, cystic fibrosis or nephrogenic 
diabetis insipidus has been the subject of several excellent reviews [11,98-101]. 
Probably, the limitations of the other GD therapeutic approaches investigated so far 
(mainly ERT) have also contributed to the increase interest in PCT. This interest is 
maintained even considering the conceptual limitations of PCT: (i) it is restricted to 
cases in which the mutant enzyme folding is chaperone-responsive, (ii) preserves certain 
residual activity itself, and (iii) a thorough mutation-based profiling of chemical 
chaperones is required to attain the expected therapeutic relevance. 
The fact that the most common mutant glucocerebrosidases are chaperone-responsive 
converted GD into a paradigmatic disease to assess the scope of PCT. Although much 
knowledge has being gained during the last decade, still major goals remain unmet. The 
limitations of IFG, the deepest investigated chemical chaperone for GD so far, might 
serve to illustrate them. IFG is an excellent glucocerebrosidase inhibitor but only 
modestly selective. IFG is such a strong inhibitor that glucocerebrosidase activity 
enhancement only takes place after it is washed out of the lysosome. In addition, IFG 
hydrophilicity limits its intracellular distribution and therefore the dose required to elicit 
the desired effect turns much higher than theoretically needed. Probably the skills to 
rationally design chaperones that specifically target the mutant enzyme in a pH-
switchable manner are the most demanded. Modulating the basicity of the chaperone, 
e.g. by replacing the amine-type nitrogen of iminosugars or azasugars into pseudoamide 
functional groups, might offer an interesting tool, but many mechanistic questions 
remain to be answered [85,102]. 
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An ideal chaperone should have weak or no inhibitory effects and high enzyme activity 
enhancing capability [103]. Future development of chemical chaperones should take full 
advantage of the HTS and computational methodologies that are being added to the 
toolbox to commit with this criterion. Leaps forward in this direction were reported 
recently. Inventions registered by Summit Corporation described a method for the 
identification of compounds from natural and synthetic iminosugar libraries that 
function as pharmacological chaperones but without inhibiting the chaperoned enzyme 
[226,227]. Further on, the same authors have shown that combination of the 
chaperoning properties towards mutant glucocerebrosidases (e. g. N370S) of “classical” 
(active-site enzyme ligands) chaperones such as IFG can be improved when co-
formulated with the non-active-site chaperones identified in their screenings [228].  
The rapid development of the field is a consequence of the contribution of a growing 
number of research teams applying their own expertise. This intuitively positive feature 
is, probably, the reason why comparison of independently obtained results is delicate. 
The methods to determine, for instance, enzyme activity enhancement differ from one to 
another and are often based on protocols that require cell lysis, which might not 
accurately reflect enzyme activity at the lysosome. Future maturation of the field will 
hopefully bring more standardized protocols, preferentially allowing determinations to 
be made in situ in living cells. A possible solution to this issue has been recently 
delineated by Aerts and co-workers by developing fluorescent probes for the highly 
efficient and specific labeling of -glucocerebrosidase molecules in intact cells in vitro 
and in vivo [104]. 
The shortage on the production of the recombinant -glucocerebrosidase Cerezyme®, 
the drug of reference for most type 1 GD patients, during the past year has dramatically 
illustrated the risks associated to single drug management of GD. The short supply 
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arose because of the temporary shutdown of Genzyme’s Allston (Massachusetts) plant 
due to a virus contamination in June 2009. The entry of new recombinant enzymes in 
the market for the treatment of GD (e.g. Velaglucerase  from Shire and, presumably, 
Taliglucerase  from Protalix-Pfizer) will surely reduce the menace as well of the costs 
of individual treatments. In any case, the use of recombinant enzyme 
biopharmaceuticals is intrinsically associated to low stability in biological media as well 
as impossibility to cross the blood brain barrier, making enzyme replacement therapy 
hopeless for neuronopathic type 2 and type 3 GD. The sub-optimal pharmacodynamics 
and pharmacokinetics of recombinant glucocerebrosidase has always been a concern 
and the development of formulations with better bioavailability, stability and efficiency, 
a battle horse. In this context PCT, based in small molecules that can be tailored to cross 
biological barriers, might complement rather than compete with ERT. It has been 
demonstrated that chemical chaperones can increase not only thermal stability of 
recombinant glucocerebrosidase but also half-life in biological media [105,106], thus 
prompting re-evaluation of “combined therapies” even for type 1 GD. For some of the 
chemical chaperones under investigation, their potential application in combined 
therapy has been already claimed. Probably, the imiglucerase half life-enhancing effect 
of ABX (3-fold at 20 M) is the best example so far reported [221]. But also 
iminosugars such as isofagomine [107], DNJ [108] or NB-DNJ [52,109] have been 
shown to exhibit beneficial effects. But the prospects of combined therapies are not only 
aimed at preparing stabilized formulations of recombinant enzymes. For instance, in 
line with earlier work of Kopito aimed at blocking ERAD [110], it has been recently 
proposed the use of pharmacological chaperones and proteasome inhibitors as a 
combined therapeutic approach to enhance lysosomal enzyme activity [111]. 
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Coordinating the efforts of the companies developing biopharmaceuticals and chemical 
chaperones with those of chemists, biochemists, biologists and clinicians involved in 
academic research may open new venues for GD treatment that, at their turn, can 
delineate the way for other LSDs as well as other folding diseases. 
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Article highlights box. 
 Active-site specific binders have the potential to assist mutant proteins to fold 
properly, acting as PCs that rescue the enzyme from cellular recycling system 
and restore its catalytic activity. 
 PCs have arisen as an alternative to overcome the limitations of ERT, currently 
the cornerstone in the treatment for lysosomal enzymopathies.  
 GD, the most prevalent lysosomal storage disorder and probably the best studied, 
is usually considered a valid model for other lysosomal enzymopathies. Lessons 
learned from GD research are valuable tools for approaching less common LSDs. 
 As a consequence of a profitable academy-industry synergy, the number of 
potential PCs is growing fast (several candidates already entered clinical phases). 
 Future studies will not exclusively focus on new molecule design for restoring 
enzyme activity but also on investigating combining PCs with other therapeutic 
approaches (e. g. ERT). 
 PCs, pharmacologic chaperones; GD, Gaucher disease; LSD, lysosomal storage 
disorder, ERT, enzyme replacement therapy.
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Table 1. List of some LSD’s with indication of the defective lysosomal enzyme and 
approximate worldwide prevalence. 
LSD defective enzyme cases per 106 newborna 
Pompe disease acid -glucosidase 25 
Gaucher disease -glucocerebrosidase 50 
Fabry disease -galactosidase A 12.5 
GM1 gangliosidosis acid -galactosidase 10 
Tay-Sachs disease -hexosaminidase A 3 
Sandhoff disease -hexosaminidase B 3 
Niemann-Pick disease acid sphigomyelinase 10 
Krabbe disease galactocerebrosidase 10 
Farber disease acid ceramidase < 1 
metacromatic leukodystrophy arylsulfatase A 6 
Hurler-Scheie disease -iduronidase 10 
Hunter disease iduronate-2-sulfatase 10 
Sanfilippo disease A heparan-2-sulfatase 14 
Sanfilippo disease B -N-acetylglucosaminidase 
Sanfilippo disease C acetyl-CoA: -glucosamine 
N-acetyltransferase 
Sanfilippo disease D N-acetylglucosamine-6-
sulfate sulfatase 
Morquio disease A acid -galactosidase 5 
Morquio disease B arylsulfatase B 
Sly disease -glucuronosidase 4 
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-mannosidosis acid -mannosidase 1 
-mannosidosis acid -mannosidase 1 
fucosidosis acid -fucosidase 5 
sialidosis sialidase < 1 
a Data retrieved from www.orpha.net (last accessed 11th Feb 2011) 
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Table 2. Clinical features of Gaucher’s disease variants. 
 Gaucher’s disease 
 Type I Type  2  Type III 
onset age childhood to 
adulthood 
newborn childhood to 
adolescence 
haematological 
affection 
+ to +++ +++ + to +++ 
visceromegalia + to +++ 
progressive 
+++ + to +++ 
progressive 
skeletal affectiona + to +++ nd + to +++ 
neuronal affection - +++ + to +++ 
live span shortened life if 
untreated 
poor life quality 
> 2 years childhood to early 
adulthood 
incidence 1 in 20000-40000 
live births 
1 in > 100000 live 
births 
1 in 50000-100000 
live births 
pan-ethnicb pan-ethnic pan-ethnicc 
- to +++ are increasing degrees of severity 
nd states for not documented due to early death 
a Over 95% of patients feature radiologic abnormalities. b Particularly high incidence 
among Askenazi Jew population, peaking up at 1 in 450 live births. c Higher incidence 
among Swedish population. 
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Table 3. Common mutations in Gaucher disease variants. 
gene mutation 
(cDNA) 
allele relative frequency 
overall (AJ)a (%) 
GD type 
association 
c.1226A>G N370S  29 (77) type I 
c.1448T>C L444P 38 (3.3) type  2  (mostly) 
c.84dupG 84gg < 1 (2.5) n. d.b 
c.115+1G>A IVS2+1G>A < 1 (12) n. d. 
a AJ stands for Askenazy Jews. b n. d. stands for not sufficiently documented. 
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Table 4. Summary of advantages and limitations of the most promising therapeutic 
approaches for GD. 
Therapy Advantages Limitations Approved 
treatments 
ERT efficiency rate for Type 1 
patients (>85%) 
poor enzyme 
biodistribution 
Cerezyme®, 
Genzyme 
greatly improved quality 
of life 
type  2  and 3 patients are 
refractory to ERT 
Veraglucerase, 
Shire 
 
long term experience costs Taliglucerase, 
Protalix-Pfizer 
SRT oral administration poor improvement-to-dose 
ratio 
Miglustat, Actelion
PCT enhanced biodistribution limited clinical experience investigational 
target the disease cause  only amenable to 
refolding “responsive” 
mutations 
GT and 
STC 
intend sustained correction procedure-related risks investigational 
target the disease cause  limited clinical experience 
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Table 5. Patenting activity concerning PCT in GD. 
Patent no.a Applicant Reference
WO2004/037373 Scripps Research Institute, San Diego, US 201 
US2003/0119874 Mount Sinai School of Medicine, New York, US 202 
US2005/0113415 203 
US2007/0021381 204 
US2008/064559 Amicus Therapeutics, New Jersey, US 205 
WO2008/144773 206 
WO2007/140212 Amicus Therapeutics, New Jersey, US 207 
US2009/0176860 208 
WO2006/133446 Amicus Therapeutics, New Jersey, US 209 
WO2008/128106 210 
WO2008/134628 211 
WO2005/046612 Amicus Therapeutics, New Jersey, US 212 
US2010/0189708 213 
WO2010/118282 
WO2010/118283 
Amicus Therapeutics, New Jersey, US 214 
215 
WO2006/136714 CNRS & Univ. Orleans, France 216 
WO2005/046611 Amicus Therapeutics, New Jersey, US 217 
US2005/0137223 218 
WO2010/046517 CSIC & Univ. Sevilla, Spain 
International Univ. Health & Welfare & Univ. Tottori, 
Japan 
219 
EP 2289853 CSIC, Barcelona, Spain 220 
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WO2009/038695 Exar Corporation, US & The Hospital for Sick 
Children, Toronto, Canada 
221 
WO2009/049421 
WO2009/049422 
The Hospital for Sick Children, Toronto, Canada 223 
224 
US2007/0166813 Weizmann Institute of Science, Rehovot, Israel 225 
WO2009/066069 
WO2010/015816 
Summit Corporation, Oxford, UK 226 
227 
WO2010/116141 Summit Corporation, Oxford, UK 228 
a Collected from free patent data bases (Espacenet and Wipo) until Nov 2010. 
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Figure, Scheme and Chart Legends 
Figure 1. Wild-type (A) vs. mutant protein trafficking pathways (B). 
Figure 2. Catabolic pathways of sphingolipids highlighting the enzymes involved in the 
most common LSDs. 
Figure 3. Chronogram of therapeutic approaches towards Gaucher disease. ERT, SRT 
and PCT stand for Enzyme Replacemet Therapy, Substrate Reduction Therapy and 
Pharmacological Chaperone Therapy, respectively. 
Figure 4. Schematic -glucocerebrosidase metabolism in healthy (A) and GD cells (B) 
and the intended effect in lysosomal performance of the distinct therapeutic approaches: 
ERT (C), SRT (D) and PCT (E) (adapted from reference [5]). 
 
Chart 1. Iminosugars under investigation as pharmacological chaperones for GD. 
Chart 2. Isofagomine derivatives under investigation as pharmacological chaperones for 
GD. 
Chart 3. Non-conventional iminosugar derivatives under investigation as 
pharmacological chaperones for GD. 
Chart 4. -Glucocerebrosidase aminocyclitol-type glycomimetics under investigation as 
pharmacological chaperones for GD. 
Chart 5. Non-glycomimetic pharmacological chaperones for GD discovered by HTS. 
 
